Patrick W. Serruys1,2, MD, PhD; Norihiro Kogame3, MD; Yuki Katagiri3, MD; Rodrigo Modolo3, MD; Pawel E. Buszman4,5, MD, PhD; Andrés Íñiguez-Romo6, MD, PhD; Javier Goicolea7, MD, PhD; David Hildick-Smith8, MD; Andrzej Ochala5, MD, PhD; Dariusz Dudek9, MD, PhD; Jan J. Piek3, MD, PhD; Joanna J. Wykrzykowska3, MD, PhD; Javier Escaned10, MD, PhD; Adrian P. Banning11, MBBS, MD; Vasim Farooq12, MBChB, PhD; Yoshinobu Onuma2, MD, PhD
1. Imperial College London, London, United Kingdom; 2. ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands; 3. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 4. Center for Cardiovascular Research and Development, American Heart of Poland, Katowice, Poland; 5. Medical University of Silesia, Katowice, Poland; 6. Department of Cardiology, Hospital Meixoeiro, Pontevedra, Spain; 7. Department of Cardiology, Hospital Puerta de Hierro, Madrid, Spain; 8. Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom; 9. Institute of Cardiology, Jagiellonian University, Krakow, Poland; 10. Hospital Clinico San Carlos IDISSC and Universidad Complutense de Madrid, Madrid, Spain; 11. Department of Cardiology, John Radcliffe Hospital, Cardiology, Oxford, United Kingdom; 12. The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Aims: The purpose of the study was to investigate whether the favourable outcomes of state-of-the-art PCI in the SYNTAX II trial, demonstrated at one year, were maintained at two-year follow-up.
Methods and results: The SYNTAX II study was a multicentre, single-arm study that investigated the impact of a contemporary PCI strategy on clinical outcomes in 454 patients with de novo three-vessel coronary artery disease, without left main disease. Clinical outcomes in SYNTAX II were compared to the predefined PCI (SYNTAX-I PCI) and coronary artery bypass graft (SYNTAX-I CABG) cohorts from the landmark SYNTAX trial (SYNTAX-I), selected on the basis of equipoise for long-term (four-year) mortality utilising the SYNTAX score II. At two years, major adverse cardiac and cerebrovascular events (MACCE: a composite of all-cause death, any stroke, myocardial infarction, or revascularisation) in SYNTAX II were significantly lower compared to SYNTAX-I PCI (13.2% vs. 21.9%, p=0.001). Furthermore, similar two-year outcomes for MACCE were evident between SYNTAX II PCI and SYNTAX-I CABG (13.2% vs. 15.1%, p=0.42).
Conclusions: At two years, clinical outcomes with the SYNTAX II strategy remained superior to the predefined SYNTAX-I PCI cohort, and similar to the predefined SYNTAX-I CABG cohort.
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
drug-eluting stentsfractional flow reserveintravascular ultrasoundmultiple vessel diseasestable angina
Coronary interventionsStable CADLeft main and multivessel disease
Read next article
Microcatheter collateral channel tracking failure in retrograde percutaneous coronary intervention for chronic total occlusion: incidence, predictors, and management